How do you want your Vasotec be delivered? Choose here!

The FDA has tentatively approved Watson’s abbreviated new drug application for Enalapril Maleate tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg. Enalapril Maleate is the generic equivalent of Merck’s ACE-inhibitor Vasotec. Watson said final approval of the…

Odyssey Pharmaceuticals is marketing 5 mg, 10 mg and 50 mg tablets of bethanechol, the generic version of Merck’s Urecholine. The drug treats bladder obstructions. Three other Merck products: hypertension drug Vasotec (enalapril maleate), Pepcid (famotidine) for ulcers and Mevacor (lovastatin) for cholesterol likely will lose patent …

Drugmaker Merck & Co. said it will invest more than US$325 million in new facilities at its five Barceloneta plants, where it produces the osteoporosis treatment Fosamax, hypertension drug Vasotec and other best-selling prescription drugs, reports The San Juan Star (April 27, 2001):

Related Results

FDA unleashes 16 g…

Merck Gets Good News On Vasotec
NEW YORK - Merck & Co.’s Vasotec, one of the new class of ACE inhibitor heart drugs, has been found not only to control blood pressure but also to reduce death rates and hospitalization. Now, Merck is faced with the pleasant task of trying to incorporate that news onto its product labeling.
According to a report pub…

EAST HANOVER, N.J. — Sidmak Laboratories Inc. has launched enalapril maleate, a hypertension treatment. The medication is available in 2.5.mg., 5-mg., 10-mg. and 20-mg. tablets in bottles of 100 and 1,000. The tablets are AB-rated bio-equivalent to Vasotec, marketed by Merck & Co.

Related Results

FDA unleashes 16 generics of VasotecMerck gets good news on VasotecWa…

BRISTOL-MYERS Squibb Company (BMS) saw its stock plunge last week on the release of clinical trial data for its anti-hypertensive drug Vanlev (omapatrilat). The data showed the drug was not superior to Merck & Co. Inc.’s Vasotec (enalapril) in the treatment of congestive heart failure (CHF).

Related Results

FDA unleashes 16 …

TargetRx–
WHO: TargetRx CEO, Mike Luby, will deliver a keynote presentation
and lead the “Sales Force Strategies and Leadership
Development” track at the upcoming WBR PharmaForce Conference.

WHAT: In his presentation, “Evaluating Sales Force Performance:
Quantity vs. Quality,” Luby will use case studies and personal
experiences working with major pharmac…

2008 Anticipated Non-GAAP EPS Range of $3.28 to $3.32, Excluding Certain Items; 2008 GAAP EPS Range of $3.45 to $3.55
2009 Anticipated Non-GAAP EPS Range of $3.15 to $3.30, Excluding Certain Items; 2009 GAAP EPS Range of $2.95 to $3.17
2009 Guidance Includes an Expected Foreign Exchange Impact of Negative 3 Percent on Revenue and a Negative 6 Percent Impact on EPS
Merck Anticipates Compound Annual Non-GAAP Revenue Growth (Including 50 Percent of Joint Venture Revenue) of 2 to 4 Percent…

Coronary artery disease (CAD) traditionally has been thought of as a progressive disease. Medical therapies have aimed at slowing its progression to reduce the risk of heart attack. A drug that could actually shr…

Business Editors & Health/Medical Writers
HAWTHORNE, N.Y.–(BUSINESS WIRE)–April 20, 2001
Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) today reported that the Company received notification from the U.S. Food and Drug Administration (FDA) for the tentative approval of its Abbreviated New Drug Application (ANDA) for Enalapril Maleate and Hydrochlorothiazide Tablets USP, 5 mg/12.5 mg and 10 mg/25 mg (Enalapril/HCTZ).
E…